Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates
Phase 2a trial of RAP-219 in refractory focal epilepsy fully enrolled and on track for topline results in September 2025
BOSTON and SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) ('Rapport' or the 'Company'), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today will host its inaugural Investor and Analyst Day, featuring presentations from Rapport's executive team on the Company's strategic priorities and updates from its clinical pipeline, including progress on the RAP-219 Phase 2a trial in focal epilepsy. The event's agenda also includes a fireside chat with key opinion leader and professor of Neurology at NYU Langone's Comprehensive Epilepsy Center, Jacqueline French, M.D., hosted by Rapport's Chief Medical Officer, Jeffrey Sevigny, M.D.
A livestream of the event and presentation materials will be available starting at 2:45 p.m. Eastern Time (ET) today and can be accessed by visiting 'News & Events' in the Investors section of the Company's website: https://investors.rapportrx.com.
'Our Phase 2a trial of RAP-219 in refractory focal epilepsy is now fully enrolled, and we remain on track to report topline results in September 2025,' said Abraham N. Ceesay, Chief Executive Officer of Rapport Therapeutics. 'This will mark a major milestone for our lead program and an opportunity to demonstrate the strength of our precision neuroscience approach. We're excited to share additional details about the trial ahead of the readout and honored to be joined by Dr. French, principal investigator of our RAP-219 epilepsy trial, who will provide valuable expert insight on the trial design and unmet need in focal epilepsy. Today's event allows us to further underscore the potential of RAP-219 as a differentiated therapeutic with broad clinical and commercial potential.'
Highlights of Rapport's Investor and Analyst Day event include the following:
Phase 2a trial of RAP-219 in refractory focal epilepsy
The Phase 2a trial of RAP-219 in refractory focal epilepsy is now fully enrolled. This proof-of-concept trial, designed with input from leading epilepsy experts, uses intracranial electroencephalography (iEEG) data from the RNS System to access RAP-219's potential effect on long episodes (LEs), an objective biomarker shown to correlate with clinical seizures (CSs).
Enrolled patients' baseline characteristicsPreliminary baseline characteristics of the first 14 patients enrolled—those for whom baseline data are available—indicate that the trial population is representative of patients historically enrolled in registrational refractory focal epilepsy trials.
Baseline Characteristics of First 14 Patients Enrolled
Median(range)
Median(1st to 4th quartile range)
Age
37 (20-61)
CS frequency per 28 days in 4-week prospective baseline
10 (4.25-18.25)
Sex (n)
7F/7M
LE frequency per 28 days in 12-week baseline (8-week retrospective + 4-week prospective)
51 (21-194)
Age at first seizure
19 (0.5-31)
Concordance between LEs and electrographic seizure (rated by an independent reviewer)
92% (71-96)
Years since RNS implantation
4.4 (1.4-10.2)
Concomitant antiseizure medications
3
Anticipated analysis of Phase 2a topline dataThe Company expects to provide the following data analysis when topline results are reported in September 2025:
Primary endpoint analysis:
Proportion of patients achieving ≥30% reduction in LEs compared with 12-week baseline period
Median percent change in LE frequency compared with 12-week baseline period
Key secondary endpoint analysis:
Median percent change in CS frequency compared with 4-week prospective baseline
Proportion of patients achieving ≥50% reduction in CSs compared with 4-week prospective baseline
Treatment-emergent adverse event (TEAE) incidence and grade
RAP-219 Phase 1 development update
Consolidated Phase 1 safety summary As disclosed in January, a total of four Phase 1 trials have been conducted—a single ascending dose trial, two multiple ascending dose trials, and a multiple ascending dose human positron emission tomography (PET) trial. Across these trials, 100 healthy volunteers have been exposed to RAP-219.
The Company's update includes data from the three completed Phase 1 multiple dose trials, including the PET trial from which final data were not available at the time of the Company's January disclosure. Final aggregate data (n=64) across the multiple dose trails continue to reinforce RAP-219's differentiated tolerability:
All TEAEs were Grade 1 or 2
No serious adverse events (SAEs), nor clinically significant laboratory, vital signs, or electrocardiogram (ECG) abnormalities
TEAEs occurred early in dosing and resolved without further action
Most common TEAEs: headache (n=12), dry mouth (n=5), brain fog (n=5), and fatigue (n=5)
Three discontinuations
Upcoming catalysts
September 2025: RAP-219 Phase 2a topline readout in focal epilepsy
Q3 2025: Initiation of RAP-219 Phase 2a trial in bipolar mania
2H 2025: Update on the Company's diabetic peripheral neuropathic pain program
1H 2027: RAP-219 Phase 2a topline readout in bipolar mania
Cash runway guidance
As of March 31, 2025, Rapport reported $285.4 million in cash, cash equivalents, and short-term investments, excluding restricted cash. These funds are expected to support operations through the end of 2026.
About RAP-219RAP-219 is a clinical-stage AMPA receptor (AMPAR) negative allosteric modulator (NAM) designed to achieve neuroanatomical specificity through its selective targeting of a receptor associated protein (RAP) known as TARPγ8, which is associated with neuronal AMPARs. Whereas AMPARs are distributed widely in the central nervous system, TARPγ8 is expressed only in discrete regions, including the hippocampus and neocortex, where focal seizures often originate. By contrast, TARPγ8 has minimal expression in the hindbrain, where drug effects are often associated with intolerable adverse events. With this precision approach, the Company believes RAP-219 has the potential to provide a differentiated profile as compared to traditional neuroscience medications. Due to the role of AMPA biology in various neurological disorders and the selective targeting of TARPγ8, the Company believes RAP-219 has pipeline-in-a-product potential and is evaluating the compound as a transformational treatment for patients with focal epilepsy, bipolar disorder, and peripheral neuropathic pain.
Availability of Other Information About Rapport TherapeuticsRapport Therapeutics uses and intends to continue to use its Investor Relations website and LinkedIn (Rapport Therapeutics) as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company's Investor Relations website and LinkedIn, in addition to following the Company's press releases, SEC filings, public conference calls, presentations, and webcasts. The contents of the Company's website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
About Rapport TherapeuticsRapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological or psychiatric disorders. The Company's founders have made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain. Their findings form the basis of Rapport's RAP technology platform, which enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport's precision neuroscience pipeline includes the Company's lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The Company is currently pursuing RAP-219 as a potential treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
Forward-Looking StatementsThis press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: the clinical development of RAP-219 for the treatment of refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain, including the initiation, timing, progress and results of our ongoing and planned clinical trials; expectations for the activity, tolerability, and commercial potential of RAP-219; the potential of Rapport's RAP technology platform; and expectations for Rapport's uses of capital, expenses and financial results, including its cash runway through the end of 2026.
Forward looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect Rapport's business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to the Company's research and development activities; Rapport's ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to preclinical and clinical development activities; the Company's dependence on third parties to conduct clinical trials, manufacture its product candidates and develop and commercialize its product candidates, if approved; Rapport's ability to attract, integrate and retain key personnel; risks related to the Company's financial condition and need for substantial additional funds in order to complete development activities and commercialize a product candidate, if approved; risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining Rapport's intellectual property protections; and risks related to the competitive landscape for Rapport's product candidates; as well as other risks described in 'Risk Factors,' in the Company's Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Rapport's subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Rapport's views only as of today and should not be relied upon as representing its views as of any subsequent date. Rapport expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
ContactJulie DiCarloHead of Communications & IRRapport Therapeuticsjdicarlo@rapportrx.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
1 Profitable Stock on Our Buy List and 2 to Question
While profitability is essential, it doesn't guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity". A business making money today isn't necessarily a winner, which is why we analyze companies across multiple dimensions at StockStory. That said, here is one profitable company that leverages its financial strength to beat the competition and two best left off your watchlist. Trailing 12-Month GAAP Operating Margin: 19.4% Founded by payroll software veteran Steve Sarowitz in 1997, Paylocity (NASDAQ:PCTY) is a provider of payroll and HR software for small and medium-sized enterprises. Why Are We Hesitant About PCTY? Estimated sales growth of 8.3% for the next 12 months implies demand will slow from its three-year trend Gross margin of 68.8% reflects its relatively high servicing costs At $176.78 per share, Paylocity trades at 6x forward price-to-sales. Dive into our free research report to see why there are better opportunities than PCTY. Trailing 12-Month GAAP Operating Margin: 10.2% Expanding its markets through acquisitions since its founding, Alamo (NSYE:ALG) designs, manufactures, and services vegetation management and infrastructure maintenance equipment for governmental, industrial, and agricultural use. Why Should You Sell ALG? Sales stagnated over the last two years and signal the need for new growth strategies Projected sales growth of 2.8% for the next 12 months suggests sluggish demand Flat earnings per share over the last two years lagged its peers Alamo's stock price of $214.51 implies a valuation ratio of 21x forward P/E. Check out our free in-depth research report to learn more about why ALG doesn't pass our bar. Trailing 12-Month GAAP Operating Margin: 11.2% Formed through the merger of 12 companies, Comfort Systems (NYSE:FIX) provides mechanical and electrical contracting services. Why Will FIX Beat the Market? Sales pipeline is in good shape as its backlog averaged 30.5% growth over the past two years Earnings per share grew by 67.6% annually over the last two years and trumped its peers Returns on capital are climbing as management makes more lucrative bets Comfort Systems is trading at $499.58 per share, or 26.7x forward P/E. Is now a good time to buy? See for yourself in our comprehensive research report, it's free. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today Sign in to access your portfolio
Yahoo
24 minutes ago
- Yahoo
1 Cash-Producing Stock with Impressive Fundamentals and 2 to Be Wary Of
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. Luckily for you, we built StockStory to help you separate the good from the bad. Keeping that in mind, here is one cash-producing company that leverages its financial strength to beat its competitors and two best left off your watchlist. Trailing 12-Month Free Cash Flow Margin: 11.8% Originally the joint-venture of four cable television companies, AMC Networks (NASDAQ:AMCX) is a broadcaster producing a diverse range of television shows and movies. Why Should You Sell AMCX? Products and services have few die-hard fans as sales have declined by 4.6% annually over the last five years Sales were less profitable over the last five years as its earnings per share fell by 16.4% annually, worse than its revenue declines Waning returns on capital from an already weak starting point displays the inefficacy of management's past and current investment decisions AMC Networks is trading at $6 per share, or 2x forward P/E. Check out our free in-depth research report to learn more about why AMCX doesn't pass our bar. Trailing 12-Month Free Cash Flow Margin: 24.7% As a pioneer in 3D mammography technology that has revolutionized breast cancer detection, Hologic (NASDAQ:HOLX) develops and manufactures diagnostic products, medical imaging systems, and surgical devices focused primarily on women's health and wellness. Why Does HOLX Give Us Pause? Constant currency revenue growth has disappointed over the past two years and shows demand was soft Expenses have increased as a percentage of revenue over the last five years as its adjusted operating margin fell by 23.2 percentage points Shrinking returns on capital suggest that increasing competition is eating into the company's profitability At $65 per share, Hologic trades at 14.5x forward P/E. Dive into our free research report to see why there are better opportunities than HOLX. Trailing 12-Month Free Cash Flow Margin: 7.2% Spun out of Post Holdings in 2019, Bellring Brands (NYSE:BRBR) offers protein shakes, nutrition bars, and other products under the PowerBar, Premier Protein, and Dymatize brands. Why Will BRBR Beat the Market? Products are flying off the shelves as its unit sales averaged 20.8% growth over the past two years Earnings per share grew by 28% annually over the last three years and trumped its peers Stellar returns on capital showcase management's ability to surface highly profitable business ventures BellRing Brands's stock price of $58.78 implies a valuation ratio of 24.6x forward P/E. Is now the right time to buy? Find out in our full research report, it's free. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today Sign in to access your portfolio
Business Wire
an hour ago
- Business Wire
Bentley Systems Wins Multiple 2025 Sustainability Delivery Awards
EXTON, Pa.--(BUSINESS WIRE)-- Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, was recognized across multiple categories at Environment Analyst's 2025 Sustainability Delivery Awards, held earlier this month in Chicago. Bentley received top honors in two award categories and was highly commended in a third, highlighting the company's continued leadership in driving innovation and measurable progress toward meeting global infrastructure sustainability objectives: Digital Innovation Award (Winner): Bentley's Carbon Analysis capabilities in iTwin Experience were recognized for their ability to enable infrastructure engineers to simplify and streamline data collection and carbon reporting, easily visualize and quantify embodied carbon, and rapidly explore alternatives for better designs, saving time and reducing risk on major infrastructure projects. Water Project of the Year (Winner): Together, Bentley and SABESP were recognized for the Integra 4.0 Cultural Transformation Through Digitalization project, which is a landmark initiative accelerating sustainable water infrastructure modernization in Brazil through digital twin technology. Energy Project of the Year (Highly Commended): Bentley, alongside Exo, were honored for the Evergy Power Transmission Structure Stabilization project, an effort that leveraged digital modeling and predictive analytics to enhance energy grid resilience. These recognitions underscore Bentley's commitment and leadership position to advancing sustainability through digital engineering solutions that enable more resilient, efficient, and low-carbon infrastructure. The water and energy projects were previously honored at Bentley's 2024 Year in Infrastructure conference: the SABESP Integra 4.0 program was recognized as a Going Digital Award winner in the Water and Wastewater category by a panel of independent jurors, while the Exo Evergy Power Transmission Structure Stabilization program received Bentley Founders Honors. 'At Bentley, our sustainability vision reflects the urgent need to future-proof global infrastructure,' said Chris Bradshaw, chief sustainability and education officer at Bentley Systems. 'Digital twins are essential for sustainable development, helping users optimally balance environmental, social, and economic outcomes. We're proud to be recognized across several categories in the 2025 Sustainability Delivery Awards and remain committed to delivering solutions that drive real progress toward climate and resilience goals.' The Sustainability Delivery Awards, hosted by Environment Analyst, celebrate innovation, leadership, and tangible progress across global infrastructure. Judged by an independent panel of industry experts, this year's awards brought together leaders and changemakers committed to transforming the infrastructure sector for a more sustainable future. # # # About Bentley Systems Around the world, infrastructure professionals rely on software from Bentley Systems to help them design, build, and operate better and more resilient infrastructure for transportation, water, energy, cities, and more. Founded in 1984 by engineers for engineers, Bentley is the partner of choice for engineering firms and owner-operators worldwide, with software that spans engineering disciplines, industry sectors, and all phases of the infrastructure lifecycle. Through our digital twin solutions, we help infrastructure professionals unlock the value of their data to transform project delivery and asset performance. © 2025 Bentley Systems, Incorporated. Bentley, the Bentley logo, and iTwin are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries. All other brands and product names are trademarks of their respective owners.
